Clinical bottom line
Cardiac iron overload is a critical complication of hereditary hemochromatosis and secondary iron-loading conditions that can lead to cardiomyopathy and heart failure if undetected. Recent advances in AI-enhanced cardiac imaging, particularly MRI, offer promising tools for early, noninvasive detection of myocardial iron deposition before clinical symptoms arise. While conventional T2* MRI remains the clinical standard for quantifying cardiac iron, AI algorithms can improve image acquisition, segmentation, and quantification accuracy, potentially enabling earlier diagnosis and risk stratification. However, current evidence is largely preliminary and hypothesis-generating, warranting further validation in prospective cohorts before routine clinical adoption.
What the evidence shows
Hereditary hemochromatosis causes systemic iron overload, with excess iron depositing in organs including the liver, pancreas, and heart (Piperno et al., 2000; Bacon et al., 2012). Cardiac iron overload is a major cause of morbidity and mortality in these patients, as iron-induced oxidative damage leads to restrictive and dilated cardiomyopathy (Singh et al., 2023). Early detection is crucial because cardiac dysfunction may be reversible with timely iron chelation therapy.
Magnetic resonance imaging (MRI) using T2* relaxation time mapping is the established noninvasive method for assessing myocardial iron concentration and correlates well with biopsy findings (Singh et al., 2023; Hartung et al., 2026). However, manual T2* measurement is time-consuming and subject to interobserver variability. AI-enhanced imaging approaches have been developed to automate and refine T2* quantification, improving reproducibility and sensitivity to subtle iron accumulation (Singh et al., 2023).
These AI methods leverage deep learning algorithms trained on large annotated datasets to segment cardiac structures and calculate T2* values rapidly. Preliminary studies suggest AI-enhanced MRI can detect early cardiac iron overload with higher accuracy than conventional techniques, potentially identifying patients at risk before overt cardiac dysfunction (Singh et al., 2023). Additionally, AI tools may integrate multi-parametric imaging data to improve diagnostic confidence.
Beyond hereditary hemochromatosis, cardiac iron overload can also occur post-liver transplantation in patients without classical genetic mutations, underscoring the need for sensitive imaging surveillance in broader populations (Papadodima et al., 2019).
Caveats and uncertainty
Despite promising early data, AI-enhanced imaging for cardiac iron overload remains largely investigational. Most studies are small, single-center, or retrospective, limiting generalizability. There is no consensus yet on standardized AI algorithms or thresholds for clinical decision-making (Singh et al., 2023). Variability in MRI hardware, protocols, and patient populations further complicates validation.
Moreover, AI models require extensive, high-quality training data with expert annotation, which is currently limited for cardiac iron imaging. Potential biases in datasets and algorithm transparency are additional concerns. Clinical outcome data linking AI-detected early iron overload to improved patient prognosis are lacking.
The cost-effectiveness and accessibility of AI-enhanced MRI in routine practice also remain to be demonstrated. Integration into existing workflows and radiologist acceptance will be critical for translation.
How this may change practice
If validated, AI-enhanced cardiac MRI could transform the early detection and management of cardiac iron overload by enabling faster, more accurate, and reproducible quantification of myocardial iron. This would facilitate timely initiation of chelation therapy, potentially preventing irreversible cardiac damage and improving survival.
Radiologists may increasingly incorporate AI tools into cardiac MRI protocols for patients with known or suspected iron overload disorders. AI could also support screening in at-risk populations such as hereditary hemochromatosis carriers or post-transplant patients.
Ultimately, AI-enhanced imaging may complement clinical and laboratory assessments, contributing to personalized monitoring strategies. However, clinicians should remain cautious and await robust prospective evidence before widespread adoption.